- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL
December 10th 2024, 7:21pm
ASH Annual Meeting and Exposition
Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.
Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL
December 10th 2024, 7:15pm
ASH Annual Meeting and Exposition
Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.
BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies
December 10th 2024, 6:45pm
ASH Annual Meeting and Exposition
BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.
Glofitamab-Based Combo Confers High Response Rates in Heavily Pretreated Relapsed/Refractory LBCL
December 10th 2024, 6:13pm
ASH Annual Meeting and Exposition
Glofitamab plus polatuzumab vedotin generated durable remissions in heavily pretreated, relapsed/refractory large B-cell lymphoma.
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
December 10th 2024, 5:37pm
ASH Annual Meeting and Exposition
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma
December 10th 2024, 5:21pm
ASH Annual Meeting and Exposition
Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
December 10th 2024, 4:07pm
ASH Annual Meeting and Exposition
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 10th 2024, 3:45pm
ASH Annual Meeting and Exposition
Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy
December 10th 2024, 2:42am
ASH Annual Meeting and Exposition
Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith
December 10th 2024, 2:31am
OncLive News Network: On Location at ASH 2024
S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.
Dr Landgren on the Utility of Tocilizumab Prophylaxis in Relapsed/Refractory Multiple Myeloma
December 10th 2024, 1:00am
ASH Annual Meeting and Exposition
C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
December 9th 2024, 11:55pm
ASH Annual Meeting and Exposition
Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.
Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma
December 9th 2024, 11:41pm
ASH Annual Meeting and Exposition
Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
Dr Sekeres on Luspatercept Plus Lenalidomide in Non–5q Deletion MDS
December 9th 2024, 10:06pm
ASH Annual Meeting and Exposition
Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.
Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL
December 9th 2024, 9:30pm
ASH Annual Meeting and Exposition
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies
December 9th 2024, 9:24pm
ASH Annual Meeting and Exposition
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.
Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML
December 9th 2024, 9:15pm
ASH Annual Meeting and Exposition
The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.
Dr Rifkin on Efficacy and Safety Data From the Dreamm-7 Trial in R/R Myeloma
December 9th 2024, 7:15pm
ASH Annual Meeting and Exposition
Robert M. Rifkin, MD, FACP, discusses the safety and efficacy of the phase 3 Dreamm-7 trial in patients with relapsed/refractory multiple myeloma.
Tisagenlecleucel Maintains Long-Term Efficacy in R/R Follicular Lymphoma
December 9th 2024, 7:05pm
ASH Annual Meeting and Exposition
Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.
Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia
December 9th 2024, 6:26pm
ASH Annual Meeting and Exposition
Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.